Clinical Pre-screening Protocol for Ovarian Cancer

ID#: NCT03877796

Age: 18 years - 66+

Gender: Female

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: April 11, 2019

End Date: December 01, 2027

Contact Information:
US
+1 405-271-8707
Europe
Summary: The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Eligibility:

Inclusion Criteria:

- Patients with histological confirmed epithelia ovarian cancer

- Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.

- Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting

- FFPE tumor tissue available

Exclusion Criteria:

- Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.

- Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Find a Clinical Trial Find Cancer Clinical Trials